Innovation breaks through CGT, and the wind and clouds gather at East Taihu Lake! A year ago, Spectrum Bio and Tong Xieyi hosted the "East Taihu Cell and Gene Therapy Industrialization Development Summit", at which the founding celebration of Spectrum Bio was held.
On July 16, Spectrum Bio, a leading CDMO institution for cell therapy, once again joined hands with Tong Xieyi to hold the "Second East Taihu Cell and Gene Therapy Industrialization Development Summit" on the first anniversary of the launch of Spectrum Bio's brand.
This is a carefully planned Chinese CGT President's Living Room event by Tong Xieyi: nearly 100 founders and CEOs of CGT's leading innovation institutions were invited to gather by the East Taihu Lake in summer. Half a day of high-end dialogue, a freehand cocktail party... Discuss the future of China's CGT drug innovation and seek win-win opportunities for cooperation between upstream and downstream of the industry chain.
During the meeting, the Tong Xieyi Cell and Gene Therapy Club elected the third board of directors.
Welcome
Gu Hongjian delivered a speech
Member of the Party Working Committee and Deputy Director of the Management Committee of Suzhou Wuzhong Economic and Technological Development Zone
Paradise Suzhou, the most beautiful Wuzhong. Many experts and big names in the cell and gene therapy industry were invited to participate in this summit. This is not only an important opportunity for Wuzhong Economic Development Zone to talk about friendship and seek common development with new and old friends, but also the most important annual exchange event in the industry.
Congratulations
Compose a new song for CGT and write about the feelings of CDMO. Recall the past and look at the Ming Dynasty. Two strategic contracts were signed to celebrate the first anniversary of the launch of the Puxin Bio brand.
Strategic signing ceremony between Spectrum Biotech and Cerebral Biotech
Spectrum Biotech COO Li Cha (left) and Cerebral Biotech BD Director Zhang Xian (right)
Spectrum Biotech brand launch one-year anniversary celebration ceremony
For 18 years, we have been together, accumulating strength and moving forward together. The CGT industry is surging, and the wise men gather again to leave their names in history.
The establishment ceremony of the third board of directors of CGT Club of Cerebral Biotech
同写意CGT俱乐部部分常务理事合影
会议期间，同写意CGT俱乐部选举产生了新一届理事长和9位常务理事会理事，讨论形成了中国细胞基因治疗产业发展倡议。
同写意CGT俱乐部旨在凝聚中国有远见和使命感的细胞基因治疗研发、临床、和产业英才，共同探索细胞基因治疗研发创新的科学内涵，促进法规指南的科学制定，交流和分享研发经验和心得，培养和造就更多产业研发人才，推动中国CGT新药开发健康发展。
Professor Wei Wensheng's video speech
Tong Xieyi CGT Club Consultant
Professor of the School of Life Sciences, Peking University
In his speech, Professor Wei said, "No technology is isolated. It must be integrated into the industrial ecosystem to play its true value, and CGT technology is no exception. I believe that the industry leaders present here have a deeper understanding of this. In my opinion, this is also the meaning of Tong Xieyi's establishment of the CGT Club, which is to create an interactive communication platform for everyone to help the development of industrial agglomeration and ecology."
范晓虎博士视频致辞
同写意CGT俱乐部常务理事
南京传奇生物前联合创始人、CSO
“中国CGT领域的发展非常迅速，也取得了一系列的进展和成就。我坚信，在CGT领域中国会领先全球。目前我们在很多细分赛道都超过了欧美欧美，这个趋势将进一步扩大。未来二三十年，CGT将成为生物医药的主流方向，希望与各位共勉。”
曰：“既加冠，益慕圣贤之道。”拳拳赤子心，无悔医药人。CGT、创新药......路漫漫其修远兮。
马军教授
同写意CGT俱乐部顾问
哈尔滨血液病肿瘤研究所所长、CSCO监事会监事长
自1997年11月FDA批准CD20单克隆抗体利妥昔单抗上市，用于治疗B细胞淋巴瘤；以及2001年5月FDA批准治疗慢性粒细胞白血病的药物小分子靶向药物甲磺酸伊马替尼上市以来，血液肿瘤进入了分子靶向治疗新时代。目前小分子靶向药物、单抗、双抗、抗体偶联药物（ADC药物）以及CAR-T细胞治疗在血液肿瘤中层出不穷，并且取得了令人鼓舞的疗效，前景非常值得期待。
王立群博士
同写意CGT俱乐部理事长
星奕昂生物创始人、董事长兼CEO
靶点单一或适应症局限、临床应用的局限、成本高昂导致价格不菲，这些都是自体细胞治疗存在的痛点。新一代免疫细胞研发产品要具有通用型、可量产化、可治疗实体瘤的特点。细胞治疗是目前创新药的热门赛道，市场潜力巨大。比赛才刚开始，创新和坚韧是成功的两大核心要素。
Academician Li Jinsong
Tong Xieyi CGT Club Consultant
Researcher of the Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences
From cloning to semi-cloning - technological progress leads scientific development
The application of semi-cloning technology includes rapid simulation of complex diseases, genetic screening in embryonic development, research on developmental regulation of imprinting, genome labeling plan, etc. In summary, semi-cloning technology based on microfertilization and cloning is conducive to promoting the research of development and disease.
Academician Zhang Dan
Foreign Academician of the Russian Academy of Engineering, Chief Scientific Officer of Shenzhen Xingwan Company
Co-founder & CSO of Kunling Pharmaceuticals
CGT drug clinical development strategy under the new environment
The challenges of clinical trials of CGT therapies include multiple aspects. First, the uniqueness of each cell gene therapy product and clinical trial. Second, the complex logistics tracking and management of cell gene products and patient cell tissue samples in clinical trials. Third, the differences in patients' responses to cell gene therapy. Fourth, countries have some special regulations and approval processes for cell gene therapy. Fifth, the qualification requirements of hospitals for cell gene therapy. The rapid development of CDMO/CRO will help the development of CGT therapies.
Roundtable Forum: Seize the CGT Innovation Highland and Live Up to the Opportunities of the Times
Under the chairmanship of Dr. Cheng Zengjiang, the initiator of the Tongxieyi Forum, the leaders of various innovation institutions introduced their respective companies' product layout and future cooperation aspirations.
漫天霞光，天地橙黄。中国CGT产业如何持续健康发展，亟需行业自律与全社会呵护。同写意CGT俱乐部，鼓励合作共赢，倡导正能量，肩负起责任担当。同写意CGT俱乐部关于中国细胞基因治疗产业发展的倡议书
The meeting of the Council
Get rid of the square round table and set up a long table. Tradition and modernity collide, simplicity and fashion coexist. You don't have to get drunk with Li Bai, you can also sprinkle the frost of the nine states, forge the love of the world, and compose a new chapter of CGT together.
The guests were toasting and the moon was on the tree branches, and the atmosphere was very lively. Innovative thoughts mixed with the chirping of cicadas and frogs, the ripples of East Taihu Lake, and the sun, moon and stars. This is a freehand wine party, and this is the Tongxieyi CEO reception room.
本是同路人，相逢何必曾相识。当酒会演变为嘉宾的歌会，行业领袖聚会也就成了企业的年会。
List of some guests attending the meeting
Li Jinsong: Researcher at the Center for Excellence in Molecular Cell Science of the Chinese Academy of Sciences, Academician of the Chinese Academy of Sciences
Ma Jun: Director of Harbin Institute of Hematology and Oncology, Chairman of the Supervisory Board of CSCO
Zhang Dan: Foreign Academician of the Russian Academy of Engineering, Chief Scientific Officer of Shenzhen Xingwan Company, Co-founder and CSO of Kunling Pharmaceuticals
Wang Liqun: Founder, Chairman and CEO of Xingyiang Bio
Li Hongjian: Chairman of Spectra Bio
Wei Dong: CEO of Boya Gene
Zhou Guoying: Chairman and CEO of Yinuo Micromedicine
Zhang Yu: CSO of Zhongyuan Xiehe
Cheng Zengjiang: Chairman of Kebeiyuan Bio
Sun Liying: CSO of Haijinger Pharmaceuticals
Zhang Xian: Head of BD of Xianbo Bio
Yang Wei: Chairman and General Manager of Lane Pharmaceuticals
Li Cha: Chief Operating Officer of Spectra Bio
Chen Qi: General Manager of WuXi Biologics China
Chen Xu: Chairman and founder of Ekosai
Cheng Jinsheng: Vice President of Dongfulong and General Manager of Life Sciences Division
Cui Wenhao: CEO of Youjia Bio
Fan Jing: Founder of Huode Bio
Hu Yang: CEO of Weiguang Gene
Kong Lingjie: CSO of Boten Bio
Li Linhong: CEO of Sesserqing
Li Xiang: Founder, CEO and CSO of Shize Bio
Li Yiping: CEO of Innovent Biologics
Li Yongfeng: Chief Marketing Officer of Spectrum Bio
Lin Qing: CEO of Lingyi Bio
Liu Bin: COO of Shenyan Bio
Liu Haiyang: CEO of Borice Bio
Liu Wei: Chairman of Huakan Bio
Liu Yarong: CEO of Shali Bio
Lv Lulu: CEO of Heyuan Bio
Shang Yuanfang: Founder and CEO of Saiqiao Bio
Shang Xiaoyun: CEO of Maoxing Bio
Su Zhenbo: Founder of Tiankeya
Sun Lele: Founder and CEO of Xuzhenda
Tian Xiaopeng: Deputy Chief Physician of Hematology Department of the First Affiliated Hospital of Soochow University
Wang Wen: CEO and CMO of Reindeer Medical
Wang Gang: CEO of Kaixia Bio
Wang Jun: Chairman and General Manager of Axis Bio
Wang Quanjun: Chief Scientist of Saifu Pharmaceuticals
Wang Tongsheng: Head of Production of Zilong Bio
Bei Peipei: Head of Quality of Zilong Bio
Wang Zifeng: Chairman of Shengyan Bio
Wu Lanlin: Co-founder and CEO of Kemeixin
Wu Qiong: Chief Business Officer and SVP of Innovent Biologics
Xiao Shan: Deputy General Manager of Naikang Bio
Xu Xianbin: Deputy General Manager of Spectrum Bio
Xu Yuanyuan: Founder and Chairman of CureGene
Yang Huanfeng: CEO of Yuanqi Bio
Yang Lin: Founder and Chairman of Boshengji Pharmaceuticals
Yang Wei: Chairman and General Manager of Lane Pharmaceuticals
Yao Shuyuan: CEO of Annolinglu Pharmaceuticals
Yuan Jijun: EVP of Abogen Bio
Zhang Jinhua: Founder and Chairman of Reindeer Medical
Zhang Ting: Founder and CEO of Genentech
Zhang Yan: Co-founder of Mega Technology
Zhang Ying: Co-founder of Zhongsheng Tracing
Zheng Weiyi: Chairman of Nobio Biotech
Zhu Fangfang: Founder of Xueji Biotech
Zhu Min: Senior Vice President of Jianxin Yuanli
Zuo Chijian: Co-founder and CSO of Cremaide
400-900-1882 
info@hillgene.com 
English
